Login / Signup

Sinus Floor Augmentation with Synthetic Hydroxyapatite (NanoBone ® ) in Combination with Platelet-Rich Fibrin: A Case Series.

Luís FranciscoManuel FranciscoRosana CostaMiguel Nunes VasquesMarta RelvasAntónio RajãoLuís Silva MonteiroPaulo RompanteFernando GuerraMarco Infante da Câmara
Published in: Biomedicines (2024)
Several techniques have been described for maxillary sinus graft augmentation, including the lateral window technique and crestal approach with osteotomes or osseodensification. Platelet-rich fibrin has been used in maxillary sinus lift procedures due to its ability to accelerate soft and hard tissue healing. The aim of this study was to evaluate the potential of PRF in combination with the synthetic hydroxyapatite NanoBone ® to enhance bone regeneration in sinus floor elevation with the lateral window technique. Out of the 50 individuals screened in a preoperative assessment visit from the CESPU-Famalicão clinical unit and intervened upon between January 2023 and December 2023, only 6 patients who met the study's inclusion criteria consented to participate. In a split-mouth study, twelve sinus graft surgeries were carried out. Our observations reveal that for the test group (NanoBone ® /PRF), there is a 27.5 ± 4.9% increase new vital bone, 23.0 ± 3.7% increase in inert bone particles, and 49.4 ± 2.8% increase in connective tissue. Meanwhile, for the control group (NanoBone ® ), there is a 19.5 ± 3.0% increase in new vital bone, 23.4 ± 5.7% increase in inert bone particles, and 57.0 ± 3.5% increase in connective tissue. The results strongly indicate that mixing liquid PRF with NanoBone ® does not have a negative influence on the amount of viable bone formation, and it seems to slightly increase the amount of new bone formation and revascularization in sinus bone graft procedures with the lateral window technique compared to the single use of NanoBone ® .
Keyphrases
  • patients undergoing
  • bone regeneration
  • bone mineral density
  • bone loss
  • soft tissue
  • minimally invasive
  • postmenopausal women
  • coronary artery disease
  • tyrosine kinase
  • single cell